You are here
Albert Kim, MD, PhD
- Professional Designation: MD, PhD, FACC, FHRS
- Group: Internal Medicine Research Unit
- Location: Cambridge, MA
- LinkedIn page URL: https://www.linkedin.com/in/albert-m-kim-8994a711/
Albert M. Kim is a physician-scientist trained in cardiology, biophysics, and engineering who joined Pfizer in 2013. At Pfizer, he has served in multiple roles over the past several years, contributing as clinical lead of early asset teams in the Cardiovascular and Metabolic Diseases Research Unit (CVMET), as co-Global Clinical Lead for the bococizumab Phase III program, and as a core member of therapeutic area strategy teams and the Cardiovascular Safety Advisory Council. His current role is Vice President, Clinical Research Head in the Internal Medicine Research Unit (IMRU). In this role, he is responsible for the clinical and translational research portfolio in the IMRU, currently focused on metabolic diseases including NASH, diabetes, and cachexia.
Dr. Kim earned his undergraduate degree in biomedical engineering from Harvard, and his MD and PhD degrees from University of California Los Angeles. He then went on to complete internal medicine residency training at Brigham and Women's Hospital, a cardiology fellowship at Massachusetts General Hospital, and clinical cardiac electrophysiology subspecialty training at University of California San Francisco (UCSF), attaining board certification in all three disciplines. Prior to joining Pfizer, he was a member of the UCSF cardiology faculty and subsequently transitioned to the pharmaceutical industry as a Senior Translational Medicine Expert at Novartis, where he led small molecule and biologic asset programs for hyperlipidemia, inflammation, atherosclerosis, and arrhythmia indications. Outside of Pfizer, he has served at the US Food and Drug Administration in the Division of Cardiac Devices as a medical reviewer and project lead for the industry guidance document on catheter ablation for atrial fibrillation. In addition, Dr. Kim has practiced internal medicine, cardiology, and cardiac electrophysiology for 18 years. He currently holds academic appointments in the VA Boston Cardiology division, at Boston University, and at Harvard Medical School.
The IMRU clinical research team focuses on the early clinical research space, designing and executing a broad spectrum of clinical trials characterizing new mechanisms and molecules. These trials range from observational and methodology studies (Phase 0), to first-in-human trials of new medicine candidates (Phase I), to proof of concept studies (Phase II) assessing the safety and efficacy of potential medicines. In the group’s history, they have addressed a diverse set of diseases across the cardiometabolic and neurologic therapeutic areas – atherosclerosis, heart failure, lipids, hyperglycemia, obesity, Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease. Currently, they are focusing on metabolic diseases and candidate medicines that address diabetes, hyperlipidemia, NASH, and cachexia. The IMRU clinical research team is comprised of talented professionals with deep experience in clinical research and translational medicine. Colleagues in the group have training as physicians, pharmacists, and clinical trialists. They partner closely with research unit scientists and the entire array of colleagues from Pfizer’s Worldwide Research Development and Global Product Development, comprising the global medicines team at various stages of development.
- Graham I,…Kim AM, et al. New Strategies for the Development of Lipid Lowering Therapies to Reduce Cardiovascular Risk. Eur Heart J Cardiovasc Pharmacother. 2018 Apr 1;4(2):119-127.
- Kim AM, Somayaji V, Dong J et al. Once‐weekly administration of a long‐acting FGF21 analogue modulates lipids, bone turnover markers, blood pressure, and body weight differently in obese hypertriglyceridemic subjects and in non‐human primates. Diabetes, Obesity and Metabolism. 2017; doi:10.1111/dom.13023
- Dong J… Kim AM, et al. Examination of the Human Cytochrome P4503A4 Induction Potential of PF-06282999, an Irreversible Myeloperoxidase Inactivator: Integration of Preclinical, In Silico, and Biomarker Methodologies in the Prediction of the Clinical Outcome. Drug Metabolism and Disposition. 2017; DOI: https://doi.org/10.1124/dmd.116.074476
- Cowie MR…Kim AM, et al. New Medicinal Products for Chronic Heart Failure: Advances in Clinical Trial Design and Efficacy Assessment. Eur J Heart Fail. 2017 Jun;19(6):718-727. doi: 10.1002/ejhf.809.
- Ridker PD…Kim AM, et al. SPIRE Investigators. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. N Engl J Med. 2017;376:1517–1526.
- University of California, San Francisco, Fellowship in Clinical Cardiac Electrophysiology, 2008
- Massachusetts General Hospital, Boston, Massachusetts, Fellowship in Cardiovascular Disease, 2006
- Brigham and Women’s Hospital, Boston, Massachusetts, Internship and residency in Internal Medicine, 2003
- University of California, Los Angeles School of Medicine, M.D., 2000
- University of California, Los Angeles School of Medicine. Ph.D., 1998
- Harvard University, Cambridge, Massachusetts., A.B. in Biomedical Engineering, 1993
AWARDS & HONORS
Pfizer W.E. Upjohn Prizes Award, 2018
Pfizer W.E. Upjohn Prizes Award, 2016
Pfizer aSPIRE Award, 2016
Novartis LEAD program nominee and participant, 2012
ACP Klinenberg Certificate of Merit, Internal Medicine, 2000
Alpha Omega Alpha, 1999
“I joined Pfizer because of the people – our research unit and company has a tangibly positive culture that rewards good science and teamwork. This made the opportunity to work with the talented colleagues here uniquely compelling.”